PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Pilot study demonstrates safety of diabetes medication for patients with Alzheimer's disease

2010-09-13
(Press-News.org) A pilot study suggests the diabetes medication pioglitazone is generally well tolerated and may warrant further study as a treatment for patients with Alzheimer's disease, according to a report posted online today that will appear in the January 2011 print issue of Archives of Neurology, one of the JAMA/Archives journals.

"Alzheimer's disease is an immense and growing public health problem," the authors write as background information in the article. "Although prescription drug therapy for the symptoms of Alzheimer's disease has been available since 1993, these agents do not fundamentally alter the pathological expression of the disease or its progressive course. The failure of several recent treatment trials directed at the beta-amyloid peptide, a key pathological correlate of Alzheimer's disease, suggests a need to explore alternative approaches to Alzheimer's disease treatment that are not focused on beta-amyloid metabolism."

Another potential therapeutic target for the treatment of Alzheimer's disease is the nuclear receptor peroxisome proliferator–activated receptor gamma, PPAR-gamma, which acts to regulate glucose and lipid metabolism. A class of drugs known as thiazolidinediones, originally developed to reduce insulin resistance in patients with type 2 diabetes, are potent agonists (trigger a response) of PPAR-gamma. To evaluate the safety of one of these medications, pioglitazone, in patients without diabetes but with Alzheimer's disease, David S. Geldmacher, M.D., of the University of Virginia Health System, Charlottesville, and colleagues conducted an 18-month, double-blind, placebo-controlled randomized controlled trial. Twenty-nine patients without diabetes but with probable Alzheimer's disease were randomly assigned to receive either pioglitazone (titrated to 45 milligrams daily) or matching placebo, along with 200 international units of vitamin E.

A total of 25 patients (12 taking pioglitazone and 13 taking placebo) completed 18 months of therapy. Two of the patients who discontinued participation in the study early had a change in caregivers status, and two withdrew their consent; no discontinuations were attributed to adverse events.

Peripheral edema, swelling of the legs and feet, was the main adverse event, affecting four patients in the pioglitazone group (28.6 percent) compared with none in the placebo group. "This is consistent with the known adverse event profile of pioglitazone," the authors write. "No group differences in laboratory measures were identified."

"No significant treatment effect was observed on exploratory analysis of clinical efficacy," they continue, noting that the study was not intended to determine treatment efficacy. Based on the results of sample size analyses, the researchers estimate that a study would need to enroll between 155 and 340 participants randomly assigned to placebo or pioglitazone to find treatment effects for patients with Alzheimer's disease. Given that trials leading to Food and Drug Administration approval of current drugs typically enrolled 250 to 500 patients, and that several ongoing trials will enroll more than 1,000, further studies to assess the clinical efficacy of pioglitazone would be feasible.

"Disappointing results of treatment trials based on the amyloid hypothesis, and the reasonable degree of safety identified in this trial, suggest that exploratory studies of thiazolidinediones remain warranted," the authors conclude. "Future studies of this class should focus on earlier stages of disease progression and be augmented by biomarkers, such as nuclear imaging techniques, to measure changes in microglial activation associated with treatment."

###

(Arch Neurol. Published online September 13, 2010. doi:10.1001/archneurol.2010.229. Available pre-embargo to the media at www.jamamedia.org.)

Editor's Note: This study was supported by a National Institute on Aging grant. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

END



ELSE PRESS RELEASES FROM THIS DATE:

Antiviral therapy associated with fewer recurring eye problems from herpes simplex virus

2010-09-13
Taking oral antiviral medications following infection with the herpes simplex virus may be associated with a reduced risk of recurring eye-related manifestations of the disease, according to a report in the September issue of Archives of Ophthalmology, one of the JAMA/Archives journals. "Herpes simplex virus (HSV) is a common cause of corneal disease and is the leading infectious cause of corneal blindness among developed nations," the authors write as background information in the article. After the initial exposure to the virus and the resulting systemic infection, ...

Repeated antibiotic use alters gut's composition of beneficial microbes, Stanford study shows

2010-09-13
STANFORD, Calif. - Repeated use of an antibiotic that is considered generally benign, because users seldom incur obvious side effects, induces cumulative and persistent changes in the composition of the beneficial microbial species inhabiting the human gut, researchers at the Stanford University School of Medicine have found. By a conservative estimate, something like 1,000 different varieties of microbes coexist harmoniously within a typical healthy person's gut, said David Relman, MD, professor of medicine and of microbiology and immunology at the medical school and ...

Children and adults see the world differently

2010-09-13
Unlike adults, children are able to keep information from their senses separate and may therefore perceive the visual world differently, according to research published today. Scientists at UCL (University College London) and Birkbeck, University of London have found that children younger than 12 do not combine different sensory information to make sense of the world as adults do. This does not only apply to combining different senses, such as vision and sound, but also to the different information the brain receives when looking at a scene with one eye compared to both ...

A new target in polycystic kidney disease

2010-09-13
In work suggesting a new approach to treating polycystic kidney disease (PKD), a leading cause of kidney failure, researchers at Children's Hospital Boston were able to block the formation of fluid-filled cysts, the hallmark of the disease, in a mouse model. Their findings, using a compound that inhibits a receptor known as c-Met, will be published in the September 13th online edition of the Journal of Clinical Investigation. PKD is the most common fatal genetic disease affecting Caucasians in the U.S. Currently, there is no approved treatment to halt cyst growth, which ...

Video games lead to faster decisions that are no less accurate

Video games lead to faster decisions that are no less accurate
2010-09-13
Cognitive scientists from the University of Rochester have discovered that playing action video games trains people to make the right decisions faster. The researchers found that video game players develop a heightened sensitivity to what is going on around them, and this benefit doesn't just make them better at playing video games, but improves a wide variety of general skills that can help with everyday activities like multitasking, driving, reading small print, keeping track of friends in a crowd, and navigating around town. In an upcoming study in the journal Current ...

New study: Serious gaps in medical journals' disclosure of physician relationships with industry

2010-09-13
(New York, NY) Nearly half the surgeons who made at least $1 million in payments from orthopedic device companies did not have that relationship published in their scientific articles, according to a study released today in the on-line edition of the Archives of Internal Medicine. The study shows that readers are not being adequately informed about conflicts of interest even when the funds involved are significant. The study, conducted by researchers at the New York-based Institute on Medicine as a Profession (IMAP), is the first of its kind to use company records ...

NYU Langone scientists find key pathway implicated in progression of childhood cancer

2010-09-13
New York (September 13, 2010) - According to a new study a protein crucial for the immune response appears to be a key player in the progression of a devastating form of childhood leukemia called T-cell acute lymphoblastic leukemia (T-ALL). Suppressing the activity of the protein kills the leukemic cells, the study shows, opening a potential avenue to new drugs that could prevent progression of the disease. Led by Iannis Aifantis, PhD, associate professor of pathology and director of the Cancer Stem Cell Program at the NYU Cancer Institute at NYU Langone Medical Center, ...

Lung cancer culprit could offer target for therapy, UT Southwestern researchers report

2010-09-13
DALLAS – Sept. 13, 2010 – A tiny molecule that spurs the progression of non-small-cell lung cancer could become a player in fighting the disease, say researchers at UT Southwestern Medical Center, who published a study on how the molecule behaves in mice in the Sept. 14 issue of Cancer Cell. Scientists have known that the molecule microRNA-21, or miR-21, is present in overabundant quantities in human tumors, including non-small-cell lung cancer (NSCLC). Until now, however, it was unclear whether miR-21 contributed to the development of lung cancer, or whether it was simply ...

UC Davis scientists find link between arthritis pain reliever and cardiovascular events

2010-09-13
DAVIS--A research team from the University of California, Davis and Peking University, China, has discovered a novel mechanism as to why the long-term, high-dosage use of the well-known arthritis pain medication, Vioxx, led to heart attacks and strokes. Their groundbreaking research may pave the way for a safer drug for millions of arthritis patients who suffer acute and chronic pain. Using metabolomic profiling to analyze murine (rodent) plasma, the scientists discovered that Vioxx causes a dramatic increase in a regulatory lipid that could be a major contributor to ...

First-of-its-kind study shows supervised injection facilities can help people quit drugs

2010-09-13
A study led by researchers at the BC Centre for Excellence in HIV/AIDS (BC-CfE) at St. Paul's Hospital and the University of British Columbia has found that supervised injection facilities such as Vancouver's Insite connect clients with addiction treatment, which in turn resulted in greater likelihood of stopping injection drug use for at least six months. The study, recently published in the peer-reviewed journal Drug and Alcohol Dependence, is the first ever to examine the link between a supervised injection facility and injection cessation. "Extensive research has ...

LAST 30 PRESS RELEASES:

Making an impact. Research studies a new side of helmet safety: faceguard failures

Specific long term condition combinations have major role in NHS ‘winter pressures’

Men often struggle with transition to fatherhood amid lack of targeted information and support

More green space linked to fewer preventable deaths in most deprived areas of UK

Immunotherapy drug pembrolizumab improves outcomes for patients with soft tissue sarcoma

A formula for life? New model calculates chances of intelligent beings in our Universe and beyond

Could a genetic flaw be the key to stopping people craving sugary treats?

Experts urge complex systems approach to assess A.I. risks

Fossil fuel CO2 emissions increase again in 2024

Winners of Applied Microbiology International Horizon Awards 2024 announced

A toolkit for unraveling the links between intimate partner violence, trauma and substance misuse

Can everyday physical activity improve cognitive health in middle age?

Updated guidance reaffirms CPR with breaths essential for cardiac arrest following drowning

Study reveals medical boards rarely discipline physician misinformation

New treatment helps children with rare spinal condition regain ability to walk

'Grow Your Own' teacher prep pipeline at the University of Louisiana at Lafayette funded by US Department of Education

Lab-grown human immune system uncovers weakened response in cancer patients

More than 5 million Americans would be eligible for psychedelic therapy, study finds

Children’s Hospital of Philadelphia researchers find community health workers play critical role in coordinating asthma care across home, school and community

Comprehensive Genomic Profiling leads to better patient outcomes, new joint study says  

Animated movie characters with strabismus are more likely to be villains, study finds

How retailers change ordering strategy when a supplier starts its own direct channel

Young coral use metabolic tricks to resist bleaching

Protecting tax whistleblowers pays off

Bioluminescent proteins made from scratch enable non-invasive, multi-functional biological imaging

New study links air pollution with higher rates of head and neck cancer

LSU researchers excavate earliest ancient Maya salt works

Building a diverse wildland fire workforce to meet future challenges

MBARI researchers discover remarkable new swimming sea slug in the deep sea

Decentralized social media ‘increases citizen empowerment’, says Oxford study

[Press-News.org] Pilot study demonstrates safety of diabetes medication for patients with Alzheimer's disease